OncView Podcast: Genomic Testing in HR+ Breast Cancer to Guide Therapy in the Extended Adjuvant Setting
In this special edition of the “Oncology Peer Review On-The-Go” podcast, CancerNetwork spoke with Vijayakrishna (VK) Gadi, MD, PhD about the current role of genomic testing in HR-positive breast cancer.
As part of its OncView video series, CancerNetwork spoke with Vijayakrishna (VK) Gadi, MD, PhD, University of Illinois College of Medicine, about the current role of genomic testing in HR-positive breast cancer and guidance on the use of genomic assays to individualize therapy in the extended adjuvant setting.
In the video series, Gadi discussed the following:
- Adjuvant Vs Extended Adjuvant Therapy in HR+ Breast Cancer
- Predictive and Prognostic Factors in HR+ Breast Cancer
- Role of Genomic Testing in HR+ Breast Cancer
- NCCN Guideline Updates for the Use of Genomic Assays in HR+ Breast Cancer
- Identifying Patients for Extended Adjuvant Therapy With the Breast Cancer Index in HR+ Breast Cancer
- Improving the Management of HR+ Breast Cancer: Next Steps
To watch more videos in CancerNetwork’s OncView series, visit cancernetwork.com.
GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer
Patients with breast cancer experience significant weight loss after using GLP-1 receptor agonists, highlighting potential benefits for obesity management in this population.
